Introduction to ctDNA Tumor Fraction in NSCLC

The landscape of treating advanced non-small cell lung cancer (aNSCLC) has evolved rapidly with the introduction of immune checkpoint blockers (ICBs). For many years, Programmed Death-Ligand 1 (PD-L1) expression has served as the primary biomarker for determining whether a patient should receive immunotherapy alone or in combination with chemotherapy. However, clinicians frequently encounter patients with high PD-L1 expression who fail to respond to monotherapy. This gap in clinical predictability has necessitated the search for more refined biomarkers. Recent evidence suggests that ctDNA tumor fraction NSCLC assessments via liquid biopsy offer a more comprehensive view of tumor burden and biology. By quantifying the proportion of tumor-derived DNA in the blood, oncologists can better understand the total systemic burden of the disease. This quantitative approach provides a dynamic alternative to tissue biopsies, which are often limited by spatial heterogeneity and sampling difficulty in advanced stages.

The Predictive Power of the 5% Threshold

Researchers recently utilized a large nationwide clinicogenomic database (CGDB) to evaluate the predictive utility of circulating tumor DNA (ctDNA) tumor fraction (TF). In a study encompassing 965 patients, they discovered that elevated ctDNA TF served as a robust prognostic indicator for worse outcomes when using ICBs. Notably, the study identified a specific cutoff point at 5% TF that fundamentally changes treatment expectations. Patients with a ctDNA TF of 5% or higher demonstrated a significant benefit from receiving a combination of ICBs and chemotherapy compared to ICB monotherapy. The hazard ratio for real-world progression-free survival was 0.58, indicating a substantial reduction in the risk of progression for those receiving the combination. Furthermore, this threshold was validated in an independent cohort, reinforcing its reliability across different clinical settings. Consequently, measuring ctDNA TF prior to starting treatment could help clinicians move beyond the limitations of PD-L1 testing to identify those who truly require more aggressive combination regimens.

Correlation with Metabolic Tumor Burden

One of the most compelling aspects of the study was the correlation between molecular data and imaging findings. In a subset of 283 patients who had paired PET scans, researchers found a significant correlation between ctDNA TF and total metabolic tumor volume (tMTV). Specifically, the study reported a Spearman\'s rho of 0.46, indicating that the amount of tumor DNA shed into the bloodstream reflects the physical metabolic activity of the tumor mass. This synergy between liquid biopsy and radiology provides a multi-dimensional view of the patient\'s disease state. Moreover, high ctDNA TF was frequently associated with specific aggressive molecular signatures, including mutations in the STK11 and KEAP1 genes. These mutations are often linked to a more immunosuppressive tumor microenvironment and poor response to standard immunotherapy. Therefore, integrating ctDNA tumor fraction NSCLC data with metabolic imaging allows for a more nuanced risk stratification, ensuring that high-burden patients receive the necessary treatment intensification from the outset.

Navigating the PD-L1 Dilemma

The clinical utility of ctDNA TF is perhaps most evident in the group of patients with PD-L1 expression of 50% or higher. Traditionally, these patients are considered ideal candidates for ICB monotherapy, such as pembrolizumab. However, the study revealed that even within this high PD-L1 subgroup, those with an elevated ctDNA TF of 5% or more still derived greater benefit from the addition of chemotherapy. Conversely, patients with low ctDNA TF (less than 5%) and high PD-L1 expression performed exceptionally well on ICB monotherapy. This finding suggests that PD-L1 levels do not always reflect the true systemic burden or the aggressive nature of the disease. By using ctDNA TF as a secondary filter, oncologists can identify the subset of high PD-L1 patients who are likely to fail monotherapy. In addition, this approach helps avoid unnecessary chemotherapy toxicity in patients with low tumor shed and high PD-L1, who are likely to achieve durable responses with immunotherapy alone.

Molecular Signatures and Prognostic Insights

The relationship between genomic alterations and ctDNA shedding provides further insight into the biological behavior of aNSCLC. The study highlighted that certain mutations, specifically in STK11, KEAP1, and SMARCA4, were significantly enriched in patients with higher tumor fractions. These genes are known to play a role in metabolic reprogramming and immune evasion, contributing to a phenotype that is resistant to single-agent ICBs. Furthermore, the prognostic value of ctDNA TF remained consistent across various clinical variables, including performance status and histology. Notably, patients with a high TF often had a lower proportion of smoking-associated signatures and a higher prevalence of complex genomic rearrangements. This suggests that ctDNA TF is not just a measure of volume but also a surrogate for the tumor\'s evolutionary complexity and aggressive potential. Consequently, incorporating these molecular insights into the initial diagnostic workup helps in tailoring personalized therapeutic strategies that address both the genomic drivers and the total tumor burden.

Future Clinical Implementation in India

As the availability of next-generation sequencing (NGS) and liquid biopsy expands in India, the clinical implementation of ctDNA TF measurement is becoming increasingly feasible. In many tertiary care centers, liquid biopsy is already used for identifying targetable mutations like EGFR or ALK when tissue is insufficient. Expanding this to include a quantitative assessment of tumor fraction could significantly enhance precision oncology workflows. However, challenges remain regarding the standardization of assays and the economic burden of comprehensive genomic profiling. Nevertheless, the potential to save costs by avoiding ineffective treatments and managing toxicities more efficiently makes ctDNA TF an attractive biomarker for the future. Additionally, as more real-world data emerges from Indian cohorts, the 5% threshold can be further refined to suit local patient populations. Ultimately, the transition toward using ctDNA tumor fraction NSCLC as a standard decision-making tool represents a significant leap forward in the quest for more effective and personalized lung cancer care.

Frequently Asked Questions

How does ctDNA tumor fraction improve decision-making over PD-L1 alone?

While PD-L1 expression is a useful marker, it often fails to account for the total systemic tumor burden or aggressive molecular signatures like STK11 mutations. Measuring ctDNA tumor fraction NSCLC provides a quantitative assessment of the tumor\'s presence in the blood. This helps identify patients who, despite high PD-L1, have a high disease burden and require the addition of chemotherapy to immunotherapy for a successful clinical outcome.

What is the significance of the 5% TF threshold in clinical practice?

The 5% threshold serves as a critical decision-making point for oncologists. Patients with a tumor fraction above this level show significantly better outcomes with combination therapy (immunotherapy plus chemotherapy) compared to immunotherapy alone. This cutoff effectively identifies individuals who are likely to experience rapid progression on monotherapy, allowing clinicians to intensify treatment early and improve the overall progression-free survival of the patient.

How do liquid biopsy results correlate with metabolic tumor burden?

Liquid biopsy results for tumor fraction show a strong correlation with total metabolic tumor volume as measured by PET scans. This means that the concentration of tumor DNA in the blood is a reliable surrogate for the physical volume and metabolic activity of the cancer cells. This correlation allows clinicians to gain insights into the total disease burden even when imaging might be inconclusive or difficult to perform frequently.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Dall\'Olio FG et al. Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer. Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-25-3917. PMID: 42440365.